XCNQ
TRUL
Market cap1.95bUSD
Jun 09, Last price
16.14CAD
Name
Trulieve Cannabis Corp
Chart & Performance
P/E
—
P/S
1.64
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.52%
Rev. gr., 5y
36.24%
Revenues
1.19b
+5.07%
Net income
-155m
L-70.56%
CFO
271m
+34.50%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Trulieve Cannabis Corp., operating through its various subsidiaries, functions as a prominent medical cannabis company. It employs a vertically integrated model, overseeing the cultivation and in-house production of its diverse product line. These offerings are then distributed through its branded Trulieve dispensaries and a home delivery service, primarily within Florida. The company provides a wide array of products, including cannabis flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. These items are marketed under distinct brands such as Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, and Roll One. As of March 16, 2022, Trulieve operated an extensive retail network comprising 162 dispensaries. This footprint included 113 locations in Florida, 19 affiliated dispensaries in Pennsylvania, 17 in Arizona, five in California, three in Maryland, two in Massachusetts, two in West Virginia, and one in Connecticut. Beyond retail, Trulieve Cannabis Corp. also maintains cultivation and processing facilities across Arizona, Colorado, Florida, Maryland, Massachusetts, Nevada, Pennsylvania, and West Virginia. Originally established in 1940 as Schyan Exploration Inc./Exploration Schyan Inc., the company officially adopted the name Trulieve Cannabis Corp. in September 2018. Its corporate headquarters are situated in Quincy, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||